期刊文献+

62例骨髓移植患者应用抗真菌药物预防的临床疗效分析

Analysis of clinical effect of antifungal agents in 62 cases of bone marrow transplant patients
下载PDF
导出
摘要 目的分析骨髓移植过程中应用抗真菌药物预防和治疗的临床疗效。方法回顾性分析近5年来我科进行的62例骨髓移植治疗的患者真菌感染的情况,以及抗真菌药物预防和治疗的应用情况。其中A组:移植前无真菌感染38例;B组:移植前有临床拟诊断真菌感染24例且在移植前病灶稳定。每例患者在移植过程中均接受各种抗真菌药物干预。结果62例患者总真菌感染率为12.9%,其中A组患者使用口服抗真菌药物预防总真菌感染率为5.26%,B组使用口服药物预防感染率为60%,使用广谱抗真菌针剂药物预防感染率是0%,口服药物加针剂预防总感染率为25%。结论骨髓移植患者真菌感染发生率高,要根据患者既往真菌感染的情况选择不同抗菌谱和抗菌强度的药物。 Objective To analyze the clinical efficacy of antifungal drug treatment in patients after bone marrow transplantation. Methods Analysis retrospectively the fungal infection rate and the application of antifungal agents in 62 cases of bone marrow transplant patients in the past 5 years in our center. Group A (38 cases) was no fungal infections before bone marrow transplantation. Group B (24 case) was of clinical diagnosis of fungal infection which is stable pre-transplant. All 62 patients accepted a variety of antifungal agents treatment in the transplant process. Results Fungal infection rate in total 62 cases was 12.9%. Of them the rate of prevent fungal infection by antifungal agents orally in group was 5.26% and 60% in group by oral drugs. The rate of broad-spectrum antifungal drug injections to prevent infection was 0%, and the rate of oral plus injection to prevent the total infection was 25%. Concltsion The incidence of fungi was high in bone marrow transplantation. The choice of different antimicrobial spectrum and intensity of antimicrobial drugs were based on patients with previous fungal infections.
出处 《国际医药卫生导报》 2009年第9期68-70,共3页 International Medicine and Health Guidance News
关键词 骨髓移植 真菌感染 抗真菌药物 预防 临床 疗效 Bone marrow transplantation Fungal infections
  • 相关文献

参考文献7

二级参考文献18

  • 1陈瑜,沈志祥,曾晓颖.伊曲康唑预防和治疗重症血液病患者真菌感染的临床观察[J].临床内科杂志,1996,13(4):25-26. 被引量:8
  • 2[1]Potter M.Strategies for managing systemic fungal infection and the place of itraconazole.J Antimicrob Chemother,2005,56(Suppl 1):S49-S54
  • 3[2]Bow EJ,et al.Antifungal prophylaxis for severely neutropenic chemotherapy recipients:a meta analysis of randomized-controlled clinical trials.Cancer,2002,94 (12):3230-3246
  • 4[3]Marr KA,et al.Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients:long-term follow-up of a randomized,placebo-controlled trial.Blood,2000,96 (6):2055-2061
  • 5[4]Winston DJ,et al.Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients.A multicenter,randomized trial.Ann Intern Med,2003,138 (9):705-713
  • 6[5]Marr KA,et al.Itraconazole versus fluconazole for prevention offungal infections in patients receiving allogeneic stem cell transplants.Blood,2004,103 (4):1527-1533
  • 7[6]Singh N.Changing spectrum of invasive candidiasis and its therapeutic implications.Clin Microbiol Infect,2001,7 (Suppl.2):S1 -S7
  • 8[7]Maschmeyer G.The changing epidemiology of invasive fungal in fections:new threats.Int J Antimicrob Agents,2006,27 (Suppl 1):S3-S6
  • 9[8]Boogaerts M,et al.Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy.A randomized,controlled trial.Ann Intern Med,2001,135 (6):412-422
  • 10[9]Bow EJ.Of yeasts and hyphae:a hematologist's approach to antifungal therapy.Hematology Am Soc Hematol Educ Program,2006,361-367

共引文献430

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部